# Clinico-pathological and Genomic Features of HER2-low Early Breast Cancer

> clinical trial · VERIFIED · 2026-07-24

Status: COMPLETED · Sponsor: Hellenic Cooperative Oncology Group · Condition: HER2-zero, HER2-low and HER2-positive Tumors Distribution Across HR Expression Categories

- Company: Hellenic Cooperative Oncology Group
- Sector: HER2-zero, HER2-low and HER2-positive Tumors Distribution Across HR Expression Categories
- Primary source: https://clinicaltrials.gov/study/NCT07561346

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.